Buckstein R, Chodirker L, Mozessohn L, Yee KWL, Geddes M, Zhu N, Shamy A, Leitch HA, Christou G, Banerji V, Brian L, Khalaf D, St-Hilaire E, Finn N, Nevill T, Keating MM, Storring J, Delage R, Parmentier A, Thambipillai A, Siddiqui M, Westcott C, Cameron C, Mamedov A, Spin P, Tang D
A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry
Article de revue Leuk Lymphoma, 2022.
Résumé | Liens: 
Teichman J, Geddes M, Zhu N, Keating MM, Sabloff M, Christou G, Leber B, Khalaf D, St-Hilaire E, Finn N, Shamy A, Yee KWL, Storring JM, Nevill TJ, Delage R, Elemary M, Banerji V, Houston B, Mozessohn L, Chodirker L, Zhang L, Siddiqui M, Parmentier A, Leitch HA, Buckstein RJ
High transferrin saturation predicts inferior clinical outcomes in patients with MDS
Article de revue Haematologica, 2022.
Résumé | Liens:
Kim DDH, Kim TS, Atenafu EG, Novitzky Basso I, Forrest D, Bence-Bruckler I, Savoie L, Busque L, Keating MM, Delage R, Xenocostas A, Liew E, Paulson K, Stockley T, Laneuville P, Lipton JH, Kamel-Reid S, Leber B
BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase
Article de revue Br J Haematol, 196 (1), 2022.
Résumé | Liens:
Amitai I, Geddes M, Zhu N, Keating MM, Sabloff M, Christou G, Leber B, Khalaf D, Leitch HA, St-Hilaire E, Finn N, Shamy A, Yee K, Storring J, Nevill T, Delage R, Elemary M, Banerji V, Chodirker L, Mozessohn L, Parmentier A, Siddiqui M, Mamedov A, Zhang L, Buckstein R
Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN study
Article de revue Br J Haematol, 194 (2), 2021.
Résumé | Liens:
Kim DDH, Novitzky-Basso I, Kim TS, Atenafu EG, Forrest D, Savoie L, Bence-Bruckler I, Keating MM, Busque L, Delage R, Xenocostas A, Liew E, Paulson K, Stockley T, Laneuville P, Lipton JH, Kamel-Reid S, Leber B
Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial
Article de revue Br J Haematol, 193 (4), 2021.
Résumé | Liens:
Simpson-Poirier K, Harnois M, Olney HJ, Sirhan S, Gratton MO, Assouline S, Laneuville P, Delage R, Mollica L, Busque L, Szuber N
Risk of infection in MPN patients in the era of Covid-19: A prospective multicenter study of 257 patients from the CML-MPN Quebec Research Group
Article de revue Am J Hematol, 96 (6), 2021.
| Liens:
Wan BA, Nazha A, Starkman R, Alibhai S, Wells RA, Geddes M, Zhu N, Keating MM, Leber B, Chodirker L, Sabloff M, Christou G, Leitch HA, St-Hilaire E, Finn N, Shamy A, Yee KWL, Storring J, Nevill TJ, Delage R, Elemary M, Banerji V, Parmentier A, Siddiqui M, Kirubananthaan A, Mamedov A, Zhang L, Buckstein R
Revised 15-item MDS-specific frailty scale maintains prognostic potential
Article de revue Leukemia, 34 (12), 2020.
| Liens:
Starkman R, Alibhai S, Wells RA, Geddes M, Zhu N, Keating MM, Leber B, Chodirker L, Sabloff M, Christou G, Leitch HA, St-Hilaire E, Finn N, Shamy A, Yee K, Storring J, Nevill T, Delage R, Elemary M, Banerji V, Lenis M, Kirubananthaan A, Mamedov A, Zhang L, Rockwood K, Buckstein R
An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring
Article de revue Leukemia, 34 (5), 2020.
Résumé | Liens:
Klil-Drori AJ, Yin H, Azoulay L, Del Corpo A, Harnois M, Gratton MO, Olney HJ, Delage R, Laneuville P, Mollica L, Busque L, Assouline SE,
Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia
Article de revue Cancer, 125 (4), 2019.
Résumé | Liens:
Leitch HA, Buckstein R, Zhu N, Nevill TJ, Yee KWL, Leber B, Keating MM, St Hilaire E, Kumar R, Delage R, Geddes M, Storring JM, Shamy A, Elemary M, Wells RA
Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS
Article de revue Leuk Res, 74 , 2018.
Résumé | Liens:
